Chromadex (OTC:CDXC), a developer of wellness and dietary products, announced the enrollment of the first patients for a collaborative human clinical study of NIAGEN.
NIAGEN is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk.
Frank Jaksch, founder and chief executive, said: “The human study is designed to provide a better understand on how NR can help people optimize their physical and metabolic functions.”
The project being conducted at the University of Copenhagen will be a placebo controlled, double-blind, randomized study of 40 obese healthy men.
It will assess the potential benefits of the supplement over the course of 12 weeks, the company said.
This new study will build upon the first successful clinical trial conducted in 2015 which demonstrated that a single dose of NIAGEN can safely elevate the co-enzyme NAD+ in the blood by as much as 2.7 times.